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Summary The purpose of this study was to evaluate in a randomized phase II trial the efficacy and toxicity of combination biochemotherapy
compared with chemotherapy alone in patients with metastatic melanoma. Sixty-five patients with metastatic melanoma (ECOG performance
status 0 or 1) were randomized to receive intravenous BCNU 100 mg m-2 (day 1, alternate courses), cisplatin 25 mg m-2 (days 1-3), DTIC
220 mg m-2 (days 1-3) and oral tamoxifen 40 mg (BCDT regimen) with (n = 35) or without (n = 30) subcutaneous interleukin 2 (IL-2) 18 x 106 iU
t.d.s. (day -2), 9 x 106 iu b.d. (day - 1 and 0) and interferon 2 alpha (IFN-a) 9 MU (days 1-3). Evidence for immune activation was determined
by flow cytometric analysis of peripheral blood lymphocytes. Treatment was repeated every 4 weeks up to six courses depending on
response. The overall response rate of BCDT with IL-2/IFN-a was 23% [95% confidence interval (Cl) 10-40%] with one complete response
(CR) and seven partial responses (PR), and for BCDT alone 27% (95% Cl 12-46%) with eight PRs; the median durations of response were
2.8 months and 2.5 months respectively. Sites of response were similar in both groups. There was no difference between the two groups in
progression-free survival or overall survival (median survival 5 months for BCDT with IL-2/IFNa and 5.5 months for BCDT alone). Although 3
days of subcutaneous IL-2 resulted in significant lymphopenia, evidence of immune activation was indicated by a significant rise in the
percentage of CD56- (NK cells) and CD3/HLA-DR-positive (activated T cells) subsets, without any change in the percentage of CD4 or CD4
T-cell subsets. Toxicity assessment revealed a significantly higher incidence of severe thrombocytopenia in patients treated with combination
chemotherapy than with chemotherapy alone (37% vs 13%, P = 0.03) and a higher incidence of grade 3/4 flu-like symptoms (20% vs 10%)
and fatigue (26% vs 13%). The addition of subcutaneous IL-2 and IFNa to BCDT chemotherapy in a randomized phase 11 trial resulted in
immune activation but did not improve response rates in patients with metastatic melanoma, and indeed may increase some treatment-
related toxicity.
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The median survival of patients with metastatic melanoma is
approximately 6 months, with less than 10% ofpatients surviving 2
years (Lakhani et al, 1990). Dacarbazine (DTIC) is the single most
active drug, but only 15-20% ofpatients respond (Rumpke, 1984).
Combination chemotherapy may improve overall response rates, in
particular the combination ofcarmustine (BCNU), cisplatin, DTIC
and tamoxifen (BCDT regimen), which has been shown to give
response rates of 30-50% (Mastrangelo et al, 1993). However,
complete remissions are rare and the duration ofresponse is gener-
ally short (3-6 months), whichever chemotherapy regimen is given.
Biological response modifiers, such as interleukin 2 (IL-2) and
interferon 2 alpha (IFN-a) have been shown to have activity
against metastatic melanoma, with objective response rates of
approximately 15-20% (Rosenberg et al, 1993). The mechanism
of response to immunotherapy may involve activation of cellular
immunity by the stimulation ofnatural killer cells orthe expansion
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of specific cytotoxic T cells. There have been several trials of
combined chemoimmunotherapy in an attempt to improve
response rates and the duration of responses by using potential
additive or synergistic interactions. Early reports ofthe addition of
IFN-a to DTIC suggested improved response rates and disease-
free survivals, although this was not borne out by subsequent
randomized trials (Falkson et al, 1991; Thomson et al, 1993;
Bajetta et al, 1994). The addition of IL-2 to chemotherapy has
been disappointing in reported phase II trials with response rates
of24-41% (Flaherty et al, 1993). Two trials ofintensive regimens
using more than one chemotherapy agent with both IL-2 (given as
i.v. infusion) and subcutaneous IFN-cx have claimed much
improved overall response rates of 57% (Richards et al, 1992;
Legha et al, 1993). However, toxicities were significant with
severe myelosuppression and a high frequency of systemic side-
effects due to the addition of IL-2 and IEN-a (fever, fatigue,
nausea and vomiting, oedema, hypotension and dermatitis).
Although these recent studies have suggested that sequential
chemoimmunotherapy may improve response rates and produce
some prolonged complete remissions, there are no randomized
trials comparing chemotherapy alone with chemotherapy and
IL-2/IFNa. Inherent bias in the selection of patients for intensive
chemoimmunotherapy schedules may explain the high response
1280BCDTwith/without IL-2/IFN 1281
rates reported in phase II studies (Richards et al, 1992; Legha et al,
1993). There are published data on the improvedtoxicity ofsubcu-
taneous IL-2 and IFN-ax in patients with renal cell cancer, with
response rates similar to those reported for high-dose intravenous
IL-2 (Buter et al, 1993; Atzpodien et al, 1995). In addition, there
are published phase II reports of responses in patients with
advanced melanoma treated with subcutaneous IL-2 and IFN-a as
sole therapy (Atzpodien et al, 1990; Castello etal, 1993). The prin-
cipal aim ofthe study was to use a subcutaneous schedule for IL-2
and IFN-ax in combination with chemotherapy to see if the
improved response rates reported for chemotherapy with intra-
venous IL-2 in melanoma could be demonstrated in patients with
advanced melanoma in a randomized trial using a better tolerated,
yet immunologically active, biotherapy regimen. Although this
moderate dose and schedule ofIL-2 and IFN has notbeenformally
studied in melanoma, the tolerability and activity of this regimen
in renal cell cancer made it reasonable to see whether there was
enhanced activity when combined with chemotherapy, provided
this was done in the context ofarandomized study. The dose ofIL-
2 used was based on experience ofthe immunological changes that
occur with IL-2 given subcutaneously, using a schedule that was
previously well tolerated (Atzpodien et al, 1993; Castello et al,
1993). Similarly, the dose ofinterferon has been used in a number
ofinterferon-DTIC studies (Falkson et al, 1991).
PATIENTS AND METHODS
Patients
Sixty-five patients (aged between 18 and 70 years) with metastatic
melanoma or locally recurrent tumour that could not be controlled
by surgery were eligible for the study. Patients were required to
have a good Eastern Cooperative Oncology Group (ECOG)
performance status of 0-1, life expectancy > 3 months and have
received no more than one previous systemic chemotherapy treat-
ment. Prior radiotherapy orbiological therapy was allowed, but all
previous treatments were stopped at least 4 weeks before entry.
Patients with cerebral metastases were excluded (although routine
computerized tomography (CT) headscan screening in asympto-
matic patients was not perforned). All eligible patients who gave
written informed consent were registered into the study and
randomized centrally (Clinical Trials Office, Institute of Cancer
Research, Sutton).
Drugs
All patients received BCDT (cycle repeated every 28 days) as
follows: day 1, BCNU (carmustine) 100 mg m-2 i.v. (administered
on alternate courses); days 1-3, cisplatin 25 mg m-2 i.v. dacar-
bazine 220 mg m-2 i.v. and tamoxifen 40 mg orally.
Those patients who were randomized to receive biochemo-
therapy received IL-2/IFN-a in addition, as follows: day -2, IL-2
18 x 106 t.d.s. s.c.; days -1 and 0, IL-2 9 x 106 b.d. s.c.; days 1-3,
interferon alpha 9 MU daily s.c. 30 min before chemotherapy.
Response and duration of therapy
All patients received two cycles of treatment, unless they had
obvious clinical evidence of disease progression before this.
Tumour response was recorded by standard WHO criteria in
measurable and assessable lesions only. Measurable lesions
included those with bidimensionable measurements, and assess-
able disease included disease that was measurable in only one
dimension. Only lytic bone lesions were considered assessable.
Complete clinical response was defined as disappearance of all
tumour on at least two observations, 4 weeks apart. Partial
response was defined as 2 50% reduction in the sum of the prod-
ucts ofall measurable lesions without any evidence ofprogression
or appearance of new lesions. Stable disease was defined as no
change (i.e. < 50% decrease or < 25% increase) in measurable or
assessable disease for at least 8 weeks, while progressive disease
was defined as > 25% increase of such disease or the appearance
of new lesions.
Patients who showed a response or stable disease in measurable
or assessable lesions after the first two cycles received two further
cycles, but only patients with disease that was continuing to
respond (PR or CR after fourcycles) proceeded with courses S and
6. Patients with clear, objective progression of disease when
reviewed for each course of treatment were withdrawn from the
study
Dose modification
Grade III/IV myelosuppression for more than 5 days resulted in a
50% dose reduction of BCNU and DTIC. Treatment was delayed
by 1 week if the absolute neutrophil count was < 1500 ul-1 or
platelet count was < 100000 p1-1. Severe fatigue and flu-like
symptoms resulted in a dose reduction of interferon by 25%. The
cisplatin dose was reduced by 50% if there was a reduction in
creatinine clearance between 50 and 60 ml min-m, andcisplatin was
stopped if clearance fell below 50 ml min-m or there was greater
than grade 2 otoxicity or neuropathy.
Clinical end points
The response of measurable and assessable sites of disease was
evaluated after two cycles of treatment as described above, and
was the primary clinical end point ofthe study. Tumour responses
(CR/PR) had to exist for greater than 4 weeks to be classified as
response, and response duration was calculated from the first
confirmed response after completing the first cycle of treatment.
Toxicity was assessed according to common toxicity criteria
(CTC) grading before each course of chemotherapy and 1 month
after the last cycle of treatment. Secondary clinical end points
included the time to disease progression and overall survival.
Immunological end points
Changes in the peripheral blood lymphocyte (PBL) phenotype
related to the total lymphocyte count were measured by flow
cytometry on day -2 (before IL-2) and day 1 (after 3 days of
subcutaneous IL-2, before any IFN-a). Monoclonal antibodies
(Coulter Electronics, Bedfordshire, UK) against the following
lymphocyte surface markers were used; CD2 (pan Tcell, reference
range 888-2870 counts ul-1); CD3 (pan T cell, reference range
815-3330 counts g1-); CD8 (cytotoxic/suppressor T cell, refer-
ence range 280-1350 counts ul-1); CD4 (helper/inducer T cell,
reference range 375-2480 counts p1-1); CD56 (natural killer cell,
NK, reference range 28-682 counts p1-1); and class II HLA-DR
(reference range 5-112 counts p1-'). Laboratory reference ranges
were derived from a maximum of28 normal laboratory volunteers
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Table 1 Patient characteristics
BCDT + IL-2 + IFN BCDT alone
No. of patients 35 30
Median age (years) 45 46
(Range) (23-68) (24-66)
Sex
Male 19 22
Female 11 13
ECOG performance status
0 21 15
1 14 15
Prior therapy
Chemotherapy 4 2
Biological therapy 1 1
Radiotherapy 3 1
Other treatment - 1
No. of disease sites
1 4 (11)a 8 (27)
2 11 (32) 10 (33)
3 12 (34) 7 (23)
24 8 (23) 5 (17)
Distribution of disease sites
Nodes 30 21
Skin 10 7
Lung 12 12
Liver 13 14
Bone 3 4
Gastrointestinal 16 9
Numbers in parentheses are percentages.
(age range 21-50 years) and are expressed as two significant
differences (s.d.) from the mean. The monoclonal antibody
required (10 gl) was added to 100 pl of whole blood (EDTA) and
vortexed. After 10 min at room temperature, the red blood cells
were lysed and the sample buffered and fixed using the Coulter G-
Prep system. The cell surface markers were then analysed as a
Coulter Epics Profile II flow cytometer. A model T-540
haematology analyser (Coulter) was used to assess total white
blood cell and lymphocyte counts; the reference ranges were 4.8-
10.8 x 109 1-1 and 1.2-3.4 x 1091-' respectively.
Statistical methods
The major end point in the study was response rate. The study was
a two-arm randomized trial with a minimum of30 patients in each
arm. It was designed as a phase II trial so that there was an 85%
chance of recommending that a phase III study be undertaken if
the difference in response rate was 20% or more favouring the
biological therapy. A large false-positive error rate (30%) was
considered acceptable because a phase III trial would detect such
an error, and because it was felt that large differences in response
rate would be required to compensate for increased toxicity due to
the addition ofbiological response modifiers. Progression-free and
overall survival curves were constructed using the Kaplan-Meier
method and analysed by the log-rank method.
The baseline peripheral blood lymphocyte subset values were
analysed between the two groups using the non-parametric
Mann-Whitney test. The changes in immunological parameters
after subcutaneous IL-2 were analysed using the Wilcoxon signed-
rank test.
Table 2 Response rate
BCDT + IL-2 + IFN BCDT alone
CR 1 (2)a
PR 7 (20) 8 (27)
NC 10 (29) 6 (20)
PD 17 (49) 16 (53)
aNumbers in parentheses are percentages.
RESULTS
Sixty-five patients with metastatic malignant melanoma who were
eligible for treatment were randomized between December 1993
and March 1996; 35 patients received BCDT chemotherapy with
IL-2 and IFN-a, and 30 patients received BCDT alone. Patient
characteristics are shown in Table 1. The two groups were well
balanced for age, sex, performance status, prior therapies and sites
ofmeasurable metastatic disease. The majority ofpatients in both
groups had visceral involvement with disease sites other than skin
and/or lymph nodes (88% and 96% respectively). All patients
were evaluable for toxicity and response.
The number of received courses of treatment was the same
between the two groups (median number of courses 2.9 and 3.0
respectively). There was no difference in the objective response
rate (CR + PR) between patients treated with BCDT + IL-2 + IFN-
a (23%, 95% confidence interval 10-40%) and those treated with
BCDT alone (27%, 95% confidence interval 12-46%) (Table 2).
One patient who received biochemotherapy attained a complete
response in multiple skin nodules, which was maintained for 10
months. There were no complete responses in those who received
BCDT alone. Partial responses were obtained in 7 out of35 (20%)
combined biochemotherapy and 8 out of 30 (27%) chemotherapy-
alone treated patients. The median duration of these objective
responses was similar: 2.8 months (range 1.1-10.7) and 2.5 months
(range 0.75-6.6), respectively, for responding patients in both
groups. The median time to attain best response was 8 weeks, and
all patients attained theirbestresponse by three cycles oftreatment.
Stabilization ofdisease (i.e. no change in tumour measurements
after at least two courses of treatment) was seen in ten (29%)
combined biochemotherapy and six (20%) chemotherapy-alone
treated patients, and in these the median time to disease progres-
sion was similar (4.8 and 4.75 months respectively). For those
with clinical evidence ofdisease progression during treatment, the
median time to disease progression was short: 1.1 and 1.5 months
for combined biochemotherapy and chemotherapy-alone patients
respectively.
Overall, there was no difference in progression-free survival
(Figure 1) and overall survival (Figure 2) between patients treated
with combined chemoimmunotherapy and chemotherapy alone.
The median survival was 5 months (range 1.2-26) for patients
treated with BCDT + IL-2 + IFN-a, and 5.5 months (range
0.5-20.5) for those treated with BCDT alone.
The sites ofmeasurable disease are shown in Table 3. The most
frequent responses were seen in lung, lymph node and cutaneous
sites ofdisease. A higher percentage oflymph node and lung sites
responded to chemotherapy alone compared with combined
biochemotherapy, but these differences were not statistically
significant. There was no difference in the time to relapse for each
site between the two treatment groups. Fourpatients in each group
relapsed during treatment with brain metastases.
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BCDT+IL-2/IFN n = 35, 0 = 33, E = 31.5
BCDT alone n = 30, 0=28, E = 29.5
Chi-squared = 0.14, d.f. = 1, P = 0.71
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BCDT+IL-2/IFN n = 35, 0 = 28, E = 25.1
BCDT alone n = 30, 0 = 23, E = 25.9
Chi-squared = 0.65, d.f. = 1, P = 0.42
Time since randomization (years)
Figure 1 Time to progression comparing patients treated with BCDT + IL-
2/lFN-a (-) vs BCDT alone (-.---------). 0, observed; E, expected
Figure 2 Overall survival comparing patients treated with BCDT + IL-2/IFN-
a (-) vs BCDT alone (-.---------). 0, observed; E, expected
Table 3 Number of objective tumour responses by individual site
BCDT + IL-2 + IFN responses BCDT alone responses
Total no. CR + PR (%) Total no. CR + PR (%)
Lymph nodes 30 2 (7) 21 6 (29)
Skin nodules 10 2 (20) 7 1 (14)
Liver 13 2 (15) 14 1 (7)
Lung 12 2 (17) 12 4 (33)
Gastrointestinal 16 2 (13) 9 3 (33)
Bone 3 1 (33) 4 2 (50)
Table 4 Pretreatment peripheral blood lymphocyte subset analysis determined by flow cytometry
BCDT + IL-2 + IFN BCDT alone Significance
(n=23) (n= 17)
CD56+ (NK cells) 238 (± 37) 212 (± 45) NS
CD3+/HLADR+ (activated T cells) 134 (± 27) 113 (± 15) NS
CD4+ (T helpercells) 771 (± 50) 756 (± 47) NS
CD8+ (T cytotoxic cells) 558 (± 54) 451 (± 69) NS
Values are expressed as cells 1ll1 (± s.e.m.), and non-parametric comparisons were made between the two groups
using the Mann-Whitney test.
We assessed whether the 3-day subcutaneous IL-2 schedule
used in this study before chemotherapy was associated with
immune activation. Before any treatment, patients in both arms of
the study (n = 23, BCDT/IL-2/IFNa and n = 17, BCDT alone) had
similar numbers ofperipheral blood lymphocyte subsets (Table 4).
Three days of subcutaneous IL-2 resulted in a significant
suppression of the total lymphocyte count in 14 patients
randomized to receive IL-2 before chemotherapy: 1.8 (± 0.2,
standard error of the mean) x 109 1-' before IL-2, falling to 0.8
(± 0.1) x 109 1-1 after IL-2, P = 0.001 (Wilcoxon signed-rank
test). Despite the significant fall in the peripheral lymphocyte
count induced by IL-2, there was a slight but significant rise in
the percentage ofNK cells and activated T-cell subsets (Table 5).
The percentage of NK cells increased to 19.8 ± 2.8% after IL-2
from 13.5 ± 2.1% before IL-2 (P = 0.048, Wilcoxon signed-rank
test), and the percentage of activated T cells rose to 13.6 ± 1.5%
after IL-2 from 8.1 ± 0.9% before IL-2 (P = 0.004). Overall, the
consequence ofthis shift in percentage distribution was a lack of
any change in the total cell count for these subsets despite the
overall lymphopenia (Table 5). There was no change in the
percentage of PBLs of the CD4 and CD8 phenotypes, and these
absolute cell counts fell.
There was a marked difference in the pattern of treatment-
related toxicity between the BCDT + IL-2 + IFN-a-treated
patients compared with those who received BCDT alone (Table 5).
Haematological toxicity was generally mild, but with combined
biochemotherapy there was a statistically significant higher inci-
dence of grade 3-4 thrombocytopenia, 37% vs 13% (P = 0.03)
(Table 6). Severe nausea and vomiting were also more frequent
patients treated with biochemotherapy, as was hepatic disturbance
(Table 6). Severe fatigue and flu-like symptoms together with
breathlessness were also more common in those treated with IL-2
+ IFN-a in addition to chemotherapy, although none ofthese other
differences were statistically significant.
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Table 5 Mean pre- and post-IL-2 peripheral blood lymphocyte subset analysis determined byflow cytomery in 14
patients with metastatic malignant melanoma randomized to receive biochemotherapy (BCDT + IL-2/IFN-a)
Before IL-2 After IL-2
(day-2) (day 1) Significance
Total lymphocyte count (x 109 1-1) 1.8 ± 0.2 0.8 ± 0.1 0.001
CD56+ (NK cells)
Cell count 237 ±48 204± 65 NS
% 13.5 ± 2.1 19.8 ± 2.8 0.04
CD3+/HLADR+ (activated T cells)
Cell count 132 ± 19 117 ± 18 NS
% 8.1 ± 0.9 13.6 ± 1.5 0.004
CD4+ (T helper cells)
Cell count 779 ± 69 337 ± 33 0.001
% 46.4 ± 3.0 43.9 ± 3.5 NS
CD8+ (T cytotoxic cells)
Cell count 500 ± 70 252 ± 54 0.001
% 28.0 ± 2.9 27.2 ± 2.9 NS
Values (± s.e.m.) are expressed both as absolute cell counts (cells Ri-') and as the mean percentage of total
lymphocyte count, taken 3 days after subcutaneous IL-2 and before BCDTchemotherapy. The significance of the
difference before and after IL-2 was analysed using the Wilcoxon signed-rank test.
Table 6 Common toxicity criteria
Grade 3-4
Toxicities BCDT+ IL-2+IFN BCDT alone
Haematological
Anaemia 1 (3)a 5 (17)
Neutropenia 7 (20) 5 (17)
Thrombocytopenia 13 (37) 4 (13)
Neurological
Motor weakness 1 (3) - (0)
Hearng loss - (0) 2 (7)
Sensory loss 1 (3) - (0)
Gastrointestinal
Nausea 6 (17) 3 (10)
Vomiting 3 (9) - (0)
Diarrhoea 1 (3) - (0)
Constipation 1 (3) 1 (3)
Hepatic disturbance 3 (9) - (0)
Fatigue 9 (26) 4 (13)
Flu-like symptoms 7 (20) 3 (10)
Oedema 1 (3) - (0)
Cardiovascular - (0) 1 (3)
Breathlessness 3 (9) - (0)
Infection 1 (3) 1 (3)
Weight loss 1 (3) - (0)
aNumbers in parentheses are percentages.
DISCUSSION
There have been very few randomized trials that have investigated
whether improved response rates could be achieved by the addi-
tion of biological therapy to conventional chemotherapy for
patients with metastatic melanoma. In one trial, a survival advan-
tage together with an improved response rate was shown for
single-agent dacarbazine (DTIC) combined with subcutaneous
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interferon alpha 2a (IFN-a) compared with DTIC alone (Falkson
et al, 1991), although this was not confirmed subsequently in two
largerrandomized trials (Thomson etal, 1993; Bajetta etal, 1994).
Interleukin 2 (IL-2) enhances the cellular immune response by
stimulating natural killer cells and specific cytotoxic T-cell expan-
sion. In phase II trials, the addition of intravenous IL-2 to DTIC
gave response rates of22-26% (Dillman et al, 1990; Flaherty etal,
1990; Stoter et al, 1991). Although these results are marginally
betterthan those obtained withDTIC alone, thepotential benefitof
IL-2 with single-agent chemotherapy has not been studied
prospectively in randomized phase III trials.
Biological therapy with combined IEN-a and IL-2 may result in
synergistic interactions, with enhanced antigen presentation due to
IFN-a-mediated up-regulation of class 1 MHC molecules and
consequent improvement in tumour recognition by IL-2-stimu-
lated cytotoxic T cells. In early non-randomized trials, the combi-
nation of both agents as sole therapy for metastatic melanoma
appeared to be superior to either agent alone (Rosenberg et al,
1989), although this was not confirmed in a subsequent random-
ized phase III trial ofhigh-dose intravenous IL-2 with or without
IFN-a (Sparano et al, 1993). The addition of biological therapy
with both IL-2 and IFN-a to chemotherapy may prove effective
because ofthe lack ofcross-resistance, as the mechanisms ofresis-
tance are different between these modes oftherapy. Intensive regi-
mens consisting of intravenous IL-2, subcutaneous IFN-a and
platinumlDTIC-based chemotherapy have been associated with
response rates of53-55% (Richards etal, 1992; Leghaet al, 1993).
Legha et al (1996) treated 30 patients with cisplatin (20 mg m-2 d
2-5), DTIC (800 mg m-2 d 1) and vinblastine (1.6 mg m-2 d 1-5,
CVD), followed on days 6-10 and 17-21 by IL-2 continuous i.v.
infusion (9 MU m-2day-') with daily subcutaneous IFN-a (5 MU),
repeating after 3 weeks. In a recently reported randomized trial,
which compared the sequence ofbiochemotherapy (i.e. CVD/BIO
vs BIO/CVD), they showed a higher response rate with
chemotherapy followed by IL-2 (66% vs 40% respectively). In a
similar biochemotherapy programme, Richards et al (1992) used
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the BCDT chemotherapy regimen with intravenous bolus IL-2
(4.5 MU m-2 every 8 h and subcutaneous IFN-a(6 MU m-2day-')
on days 4-8 and 17-21, repeating after 3 weeks. Of 74 patients
treated, the overall response rate was 55% (CR 15%) with a
median length of survival exceeding 15 months. While both
these studies imply a high response rate for combination
biochemotherapy, to date this has not been examined compared
with chemotherapy alone in a prospective randomized clinical
trial. This is particularly important in view of the severity of the
toxicitiesreported in thesephase IItrials,includingmyelosuppres-
sion and constitutional effects, such as fever, fatigue, nausea and
vomiting, oedema and hypotension. Furthermore, the correct
sequence of chemoimmunotherapy requires clarification, as this
has variedconsiderably inprevious reports.
In our randomized trial, we chose the BCDT regimen as the
standard chemotherapy regimen, based on the phase II data avail-
able at the time, which suggested this to be the most active
regimen (DelPrete et al, 1994). In view of the severe toxicities
experienced by the addition of intravenous IL-2 to chemotherapy
(Richards et al, 1992; Legha et al, 1993; Legha et al, 1996), we
elected for a subcutaneous delivery for IL-2. The reduced toxicity
and improved tolerability of low-dose subcutaneous IL-2 is well
documented (Castello et al, 1993) and has been shownpreviously
to induce clear changes in immunological parameters with a
significant rise in NK cells (Azpodien et al, 1993). In our study,
the IL-2 was administered in a priming dose 3 days before
chemotherapy with a view to mobilizing cytotoxic T cells to
interact with chemotherapy-damaged tumour cells. Similarly, the
IFN-a was administered concurrently with the 3 days of
chemotherapy to maximize the activation ofthe immune response
during chemotherapy. Biological therapy with IL-2 before
chemotherapy has been administered previously in a series of 27
patients with areported response rate of37%,including a 12% CR
rate (Demchak et al, 1991). In addition, previous investigators
have administered infusional IL-2 before DTIC (Stoter et al,
1991). However, the combination of 3 days subcutaneous
moderate-dose IL-2 before chemotherapy followed by 3 days of
interferon has not been used in patients with melanoma before.
Our study was set up befoXre the results of the recent randomized
study reporting a superior response rate for chemotherapy
followedbybiotherapy(Legha et al, 1996).
Ourstudy failed to show any benefit for the addition ofsubcuta-
neous IL-2 and IFN-a to combination chemotherapy in terms of
response rate, progression-free survival or overall survival. Two
groups were well balanced for knownprognostic factors including
age, sex, number and distribution of disease sites, performance
status and priortherapy. Both groups received a similar number of
cycles of treatment (median three courses in each group). For the
chemotherapy-alone group, the objective response rate of 27%
appears somewhat lower than the 50% response rate reported in
previous phase II studies of BCDT (DelPrete et al, 1994).
Response rates arefrequently lowerin randomized trialscompared
withearlyphase II data, and ofnote a similar response rate of30%
was reported recently for BCDT in the Canadian randomized trial
of this regimen with/without tamoxifen (Rusthoven et al, 1996).
Very few CRs were reported in that trial (<5%), and none were
detected in ourchemotherapy-alone group.
There was an increase in some grade 3/4 toxicity in patients
who received combined biochemotherapy with BCDT and
IL-2/IFN-a, with, inparticular, asignificantly higher incidence of
thrombocytopenia (37% vs 13%). The most obvious non-haemato-
logical toxicities included fatigue, flu-like symptoms of fever and
chills, and nausea and vomiting. These toxicities are well recog-
nized in patients receiving IL-2 and IFN-a therapy. However, in
contrast to the studies ofhigh-dose intravenous IL-2 and subcuta-
neous IFN-a with chemotherapy (Richards et al, 1992; Legha et
al, 1993; Legha et al, 1996), the severity and incidence of these
toxicities was lower in our study.
The importance of dose, route of delivery and schedule for
biological therapy remains to be determined. In the adjuvant
setting, a clear survival benefit has been reported for high-dose
IFN delivered initially at a dose of 20 MU m-2 intravenously
every 5 days for4 weeks, followed by 10 MU m-2 subcutaneously
three times a week for48 weeks (Kirkwood et al, 1996). Whether
the lack of benefit in previous adjuvant studies was related to
lower doses of IFN or mode of administration (s.c.) is unclear.
The high response rates in phase II studies of biochemotherapy
that use intravenous doses of IL-2 are badly tolerated by patients
of poor performance status and bulk tumour burden, and it
remains to be seen in a randomized trial whether the benefit of
these intensive regimens is real or not. It is possible that, as with
renal cell carcinoma, only patients with a minimal tumour will
benefit from strategies that include immunotherapy. A recent
randomized trial of intravenous IL-2/IFN-a (s.c.) with/without
cisplatin demonstrated higher efficacy for combined bio-
chemotherapy (response rate 36% vs 15%, P = 0.01), but failed to
show any improvement in progression-free or overall survival
(Keilholtz et al, 1996). If dose is important, then it could be
argued that we failed to deliver sufficient biological therapy by
the subcutaneous route to have any synergistic effect. This
appears unlikely because of evidence of an immunological effect
in patients treated with biochemotherapy manifest as overall
lymphopenia with a relative increase in the percentage of CD56
NK cells and CD3+/HLADR+ activated T cells (Table 5), an
effect that was similar to that observed from our previous studies
ofintra-arterial IL-2 in head and neck cancer (Dadian et al, 1993).
It remains unclear whether the changes in overall and subset
lymphocyte counts represent a compartment phenomenon (subset
analysis after IL-2 was finished was not performed), or whether
these changes are clinically relevant in terms of an immunolog-
ical response against the tumour. However, the enhanced toxicity
of biochemotherapy compared with chemotherapy alone would
indicate that sufficient biotherapy was being administered to have
a systemic effect. Furthermore, there are published data
suggesting that low-dose IL-2 may be more effective in vivo than
higher doses in selectively activating the CD56bright NK subset,
which contains high-affinity IL-2 receptors, without activation of
monocytes or lymphocytes (Caliguri et al, 1993).
It remains to be determined whether biochemotherapy is more
effective than chemotherapy alone in the management ofpatients
with metastatic melanoma. As we initially considered that a 20%
improvement in response rate would be necessary to counter-
balance any additional toxicity due to the addition of biological
therapy, we concluded from this randomized phase II study in
which the difference in response rates was 4% (95% CI- 17-25%)
that a larger phase III study using this regimen was not indicated.
Thus, despite a tolerable IL-2/IFN-a biological therapy regimen
that resulted in immune activation, little benefit is obtained by
including this with conventional BCDT chemotherapy, at the cost
ofsignificantly enhanced patient toxicity.
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